EurekaMag.com logo
+ Translate

Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer


, : Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Research 54(1): 16-20

The HER-2/neu protooncogene is amplified and overexpressed in 20-40% of invasive breast cancers. HER-2/neu protein overexpression is associated with aggressive disease and is an independent predictor of poor prognosis in several subsets of patients. The protein may also be related to cancer formation, with overexpression being detectable in 50-60% of ductal carcinomas in situ. It has been suggested that it might be possible to develop specific T-cell therapy directed against proteins involved in malignant transformation. One question is whether normal proteins that are overexpressed are appropriate targets for therapeutic immune attack. This report demonstrates that some patients with HER-2/neu-positive breast cancers have both existent CD4+ helper/inducer T-cell immunity and antibody-mediated immunity to HER-2/neu protein. Initial studies performed on 20 premenopausal breast cancer patients identified antibodies to HER-2/neu in 11 individuals. Similar antibody responses have been found in some normal individuals. The patient with the greatest antibody response was studied in detail. In addition to a humoral immune response this patient had evidence of a significant proliferative T-cell response to the HER-2/neu protein and peptides. Similar T-cell responses have been detected in additional patients. It has been assumed that patients would be immunologically tolerant to HER-2/neu as a self-protein and that immunity might be difficult to generate. If immunity could be generated, the result might be destructive autoimmunity. The current data support the notion that HER-2/neu-specific immunity might be used in therapy without destroying normal tissue but also raises questions as to the role of existent immunity in immune surveillance and cancer progression.

(PDF 0-2 workdays service)

Accession: 008650128

PMID: 7505195

Submit PDF Full Text: Here


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Disis, M.L.; Gralow, J.R.; Bernhard, H.; Cheever, M.A., 1994: Existent T cell and antibody immunity to HER-2/neu protein in breast cancer patients. Proceedings of the American Association for Cancer Research Annual Meeting 35(0): 498

Disis, M.L.; Knutson, K.L.; Schiffman, K.; Rinn, K.; Mcneel, D.G., 2000: Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Immunomodulatory strategies, such as antibody therapy and cancer vaccines, are increasingly being considered as potential adjuvant therapies in patients with advanced stage breast cancer to either treat minimal residual disease or prevent relapse....

Disis, M.L.; Knutson, K.L.; Schiffman, K.; Rinn, K.; McNeel, D.G., 2000: Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Immunomodulatory strategies, such as antibody therapy and cancer vaccines, are increasingly being considered as potential adjuvant therapies in patients with advanced stage breast cancer to either treat minimal residual disease or prevent relapse....

Rentzsch, C.; Kayser, S.; Stumm, S.; Watermann, I.; Walter, S.; Stevanoviç, S.; Wallwiener, D.; Gückel, B., 2003: Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells. Breast cancers are known to frequently (over)express several well-characterized tumor-associated antigens (TAAs) such as carcinoembryonic antigen, MUC-1, Her-2/neu, and cancer/testis antigens such as NY-ESO-1, SSX-2, and members of the MAGE family...

Anonymous, 2007: Patients with breast or ovarian cancer have elevated T cell immunity to insulin-like growth factor binding protein 2 (IGFBP2)

Avigan, D.; Vasir, D.; Gong, J.; Wu, Z.; Borges, V.; Uhl, L.; Smith, T.; Schadt, K.; Tetreault, J.C.aude; Giallombardo, N.; Kufe, D., 2002: Vaccination with Dendritic Cell -Breast Cancer Fusions Induces Tumor Specific Immunity and Clinical Response in Patients with Metastatic Breast Cancer. Fusions of carcinoma cells and dendritic cells (DC) have been developed as a vaccine for the induction of anti-tumor immunity. The heterokaryons generated by carcinoma cell-DC fusions combine the machinery needed for immune stimulation with presen...

Ward, R.L.; Hawkins, N.J.; Coomber, D.; Disis, M.L., 1999: Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. The HER-2/neu protein is overexpressed in approximately 20% of human adenocarcinomas and is a defined tumor antigen in breast cancer. The purpose of this study was to evaluate the endogenous HER-2/neu specific antibody response in 57 patients with...

Ward, R.L.; Hawkins, N.J.; Coomber, D.; Disis, M.L., 1999: Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. The HER-2/neu protein is overexpressed in approximately 20% of human adenocarcinomas and is a defined tumor antigen in breast cancer. The purpose of this study was to evaluate the endogenous HER-2/neu specific antibody response in 57 patients with...

Lykkesfeldt A.E.; Rose C.; Thorpe S.M.; Laursen I.; Lykkesfeldt G.; Briand P., 1988: Reversible inhibitory activity of sera from breast cancer patients on estrogen effect on cell proliferation and protein synthesis of the human breast cancer cell line mcf 7. Sera from foetal calves, newborn calves, athymic mice, and healthy postmenopausal woman exert a growth inhibitory effect on the oestrogen receptor positive human breast cancer cell line MCF-7. This inhibitory effect of serum can be abrogated by oe...

Nagorsen, D.; Scheibenbogen, C.; Schaller, G.; Leigh, B.; Schmittel, A.; Letsch, A.; Thiel, E.; Keilholz, U., 2003: Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients. There is increasing evidence that tumors elicit specific T-cell responses in a substantial proportion of patients. Recently, we have shown that in patients with colorectal cancer specific T cells against the tumor-associated antigens (TAA) Ep-CAM,...